FDA Advisers Back Replimune Skin Cancer Drug; Shares Surge
Replimune shares surged after FDA advisers backed the company's skin cancer drug, an oncolytic immunotherapy now awaiting a formal regulatory decision.
Topic
Oncolytic Immunotherapy
Topic
Oncolytic Immunotherapy
TUDRIQEV Is Now Available in the U.S. for Advanced Melanoma
Replimune's TUDRIQEV oncolytic immunotherapy is now commercially available in the U.S. for advanced melanoma, moving the platform…